Opana
Drug Pain
NDC 63481-812-20
General payments
$6,266
Research payments
$242,118
Through program year 2024, $6,266 in general payments and $242,118 in research payments were reported against Opana (Pain).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $18,209 | 12 |
| 2023 | Research | $110,331 | 29 |
| 2022 | Research | $11,439 | 14 |
| 2021 | General | $6,171 | 5 |
| 2021 | Research | $39,248 | 15 |
| 2020 | Research | $56,791 | 28 |
| 2019 | General | $95 | 1 |
| 2019 | Research | $6,100 | 14 |
Breakdown
Each share is of general payments naming this product in 2021.
Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2021 where a state was reported.
Records
6 general · 112 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.